Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Michael A. Zasloff sold 63,624 shares of the firm’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $18.18, for a total value of $1,156,684.32. Following the transaction, the director now owns 101,879 shares of the company’s stock, valued at $1,852,160.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of Amphastar Pharmaceuticals, Inc. (AMPH) opened at 18.96 on Friday. The firm has a 50-day moving average price of $16.25 and a 200-day moving average price of $16.08. Amphastar Pharmaceuticals, Inc. has a one year low of $12.05 and a one year high of $21.75. The company has a market capitalization of $875.86 million, a P/E ratio of 246.23 and a beta of 1.69.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings results on Wednesday, August 9th. The company reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.05. The business had revenue of $65.20 million during the quarter, compared to analyst estimates of $63.40 million. Amphastar Pharmaceuticals had a return on equity of 2.42% and a net margin of 1.61%. Amphastar Pharmaceuticals’s quarterly revenue was down 4.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.23 EPS. Equities analysts forecast that Amphastar Pharmaceuticals, Inc. will post $0.27 earnings per share for the current year.

Amphastar Pharmaceuticals declared that its board has approved a share repurchase plan on Wednesday, August 9th that allows the company to buyback $20.00 million in shares. This buyback authorization allows the company to reacquire up to 2.8% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s board of directors believes its stock is undervalued.

COPYRIGHT VIOLATION WARNING: “Insider Selling: Amphastar Pharmaceuticals, Inc. (AMPH) Director Sells $1,156,684.32 in Stock” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this piece of content can be read at https://www.watchlistnews.com/insider-selling-amphastar-pharmaceuticals-inc-amph-director-sells-1156684-32-in-stock/1611820.html.

A number of equities analysts have recently issued reports on AMPH shares. TheStreet upgraded Amphastar Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Monday, June 26th. Needham & Company LLC raised their price objective on Amphastar Pharmaceuticals from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, September 27th. Piper Jaffray Companies restated a “buy” rating and set a $19.00 price objective on shares of Amphastar Pharmaceuticals in a research report on Sunday, September 17th. Jefferies Group LLC restated a “buy” rating and set a $19.00 price objective (down from $20.00) on shares of Amphastar Pharmaceuticals in a research report on Friday, August 11th. Finally, Wells Fargo & Company restated a “buy” rating on shares of Amphastar Pharmaceuticals in a research report on Saturday, July 22nd. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $20.17.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Argent Capital Management LLC bought a new position in Amphastar Pharmaceuticals during the 2nd quarter valued at approximately $1,069,000. The Manufacturers Life Insurance Company raised its position in Amphastar Pharmaceuticals by 1.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 28,701 shares of the company’s stock valued at $512,000 after purchasing an additional 312 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Amphastar Pharmaceuticals by 25.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,331,842 shares of the company’s stock valued at $23,786,000 after purchasing an additional 270,654 shares during the last quarter. Parametric Portfolio Associates LLC raised its position in Amphastar Pharmaceuticals by 72.0% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 45,615 shares of the company’s stock valued at $815,000 after purchasing an additional 19,091 shares during the last quarter. Finally, Nordea Investment Management AB raised its position in Amphastar Pharmaceuticals by 12.8% during the 2nd quarter. Nordea Investment Management AB now owns 115,607 shares of the company’s stock valued at $2,065,000 after purchasing an additional 13,121 shares during the last quarter. 44.26% of the stock is owned by institutional investors and hedge funds.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.